Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of Programmed Cell Death Ligand 1 and Neutrophil to Lymphocyte Ratio to Predict Response to Nivolumab in Non-Small Cell Lung Cancer

NCT03816657 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT03816657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of Programmed Cell Death Ligand 1 and Neutrophil to Lymphocyte Ratio to Predict Response to Nivolumab in Non-Small Cell Lung Cancer
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Observational
Overall status
Unknown status
Start date
February 15, 2015
Completion date
March 30, 2019
Enrollment
93 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

to define an easy and feasible panel which may be routinely applied to select patients for immunotherapy avoiding more complex and expensive methods